The American College of Lifestyle Medicine (ACLM) has published a position paper calling for the implementation of lifestyle medicine as a high-value care solution that delivers on the Quintuple Aim-better health outcomes, higher patient and clinician satisfaction, greater health equity, and lower costs. The paper includes five position statements asserting that lifestyle medicine-a rapidly growing…
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. The Food and Drug Administration…
Lowering arsenic levels in groundwater decreases death rates from chronic disease: JAMA We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Isabella Cueto covers the leading causes of death and disability: chronic diseases. Her focus includes autoimmune conditions and diseases of the lungs, kidneys, liver (and more). She writes about intriguing research, the promises and pitfalls of treatment, and what can be done about the burden of disease. You can reach Isabella on Signal at isabellacueto.03….
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A pill designed to further lower cholesterol in people already on statins but at risk of a serious cardiovascular event — their first or a recurrence — reduced LDL…
Elizabeth Cooney is a cardiovascular disease reporter at STAT, covering heart, stroke, and metabolic conditions. You can reach Liz on Signal at LizC.22. NEW ORLEANS — A cholesterol-lowering injection that’s been on the market for nearly a decade has now shown its power to cut cardiovascular events in people considered at high risk but who…
ANDREW CABALLERO-REYNOLDS/AFP via Getty Images Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp.100. Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry…
WASHINGTON — The Trump administration announced a deal Thursday to expand access to popular obesity drugs made by Novo Nordisk and Eli Lilly — offering more coverage for Medicare and Medicaid beneficiaries and lowering the prices across the board. The administration argued that giving millions more people access to these drugs represents a major victory…
Obesity Linked to Increased Severity of Periodontitis, suggests study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
WASHINGTON — The Trump administration is nearing deals with Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs and expand access to them, people familiar with the talks told STAT. The companies have been close to a deal for weeks, one lobbyist with knowledge of the negotiations said, echoing others who…